Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Pearson

Showing results (71-80 of 195) with videos related to

Pageof 20
Sort By:
British Journal of Cancer|January 8, 2004
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokineticsM Cole, L Price, A Parry, et al.
Cancer Genetics and Cytogenetics|July 18, 2006
APC and CTNNB1 mutations are rare in sporadic ependymomasOlabisi E Onilude, Meryl E Lusher, Janet C Lindsey, et al.
Pediatric Blood & Cancer|January 3, 2013
Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experienceLucas Moreno, Sucheta J Vaidya, C Ross Pinkerton, et al.
British Journal of Cancer|February 17, 2005
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cellsJ L Armstrong, M Ruiz, A V Boddy, et al.
Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.
British Journal of Cancer|April 14, 2005
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancerI Willits, L Price, A Parry, et al.
British Journal of Cancer|April 29, 2010
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task ForceK K Matthay, B Shulkin, R Ladenstein, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2009
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patientsGareth J Veal, Michael Cole, Julie Errington, et al.
Bone Marrow Transplantation|July 24, 2008
28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 proceduresR Ladenstein, U Pötschger, O Hartman, et al.
Plos One|March 27, 2014
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaYann Jamin, Laura Glass, Albert Hallsworth, et al.
Pageof 20

Showing results (71-80 of 195) with videos related to

Sort By:
Pageof 20
British Journal of Cancer|January 8, 2004
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokineticsM Cole, L Price, A Parry, et al.
Cancer Genetics and Cytogenetics|July 18, 2006
APC and CTNNB1 mutations are rare in sporadic ependymomasOlabisi E Onilude, Meryl E Lusher, Janet C Lindsey, et al.
Pediatric Blood & Cancer|January 3, 2013
Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experienceLucas Moreno, Sucheta J Vaidya, C Ross Pinkerton, et al.
British Journal of Cancer|February 17, 2005
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cellsJ L Armstrong, M Ruiz, A V Boddy, et al.
Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.
British Journal of Cancer|April 14, 2005
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancerI Willits, L Price, A Parry, et al.
British Journal of Cancer|April 29, 2010
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task ForceK K Matthay, B Shulkin, R Ladenstein, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2009
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patientsGareth J Veal, Michael Cole, Julie Errington, et al.
Bone Marrow Transplantation|July 24, 2008
28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 proceduresR Ladenstein, U Pötschger, O Hartman, et al.
Plos One|March 27, 2014
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaYann Jamin, Laura Glass, Albert Hallsworth, et al.
Pageof 20